Inspira Technologies Oxy B.H.N Yönetim

Yönetim kriter kontrolleri 4/4

Inspira Technologies Oxy B.H.N CEO'su Dagi Ben-Noon, Jul2017 tarihinde atandı, in görev süresi 7.33 yıldır. in toplam yıllık tazminatı $ 521.19K olup, şirket hissesi ve opsiyonları dahil olmak üzere 51.6% maaş ve 48.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.77% ine doğrudan sahiptir ve bu hisseler $ 444.37K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.3 yıldır.

Anahtar bilgiler

Dagi Ben-Noon

İcra Kurulu Başkanı

US$521.2k

Toplam tazminat

CEO maaş yüzdesi	51.6%
CEO görev süresi	7.3yrs
CEO sahipliği	1.8%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Inspira Technologies reports 1H results

Aug 11

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Jul 06

CEO Tazminat Analizi

Dagi Ben-Noon'un ücretlendirmesi Inspira Technologies Oxy B.H.N'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	US$521k	US$269k	-US$11m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$1m	US$369k	-US$15m

Tazminat ve Piyasa: Dagi 'ın toplam tazminatı ($USD 521.19K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 646.00K ).

Tazminat ve Kazançlar: Dagi 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dagi Ben-Noon (48 yo)

7.3yrs

Görev süresi

US$521,190

Tazminat

Mr. Dagi Shachar Ben-Noon has been the Chief Executive Officer of Inspira Technologies Oxy B.H.N. Ltd. since July 2020 and has been its Director since March 2020.Mr. Ben-Noon served as Chief Operations Of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dagi Ben-Noon	Co-Founder	7.3yrs	US$521.19k	1.77% $ 444.4k
Joe Hayon	Co-Founder	7.3yrs	US$523.73k	3.4% $ 854.9k
Yafit Tehila	Chief Financial Officer	2.3yrs	US$326.81k	0.59% $ 147.9k
Avi Shabtai	COO and VP of Research & Development	4.3yrs	US$395.17k	1.72% $ 432.0k
Daniella Yeheskely-Hayon	Chief Technology Officer	2.8yrs	US$279.45k	0.26% $ 66.1k
Meshira Greenberg	Administrative Manager	1.8yrs	Veri yok	Veri yok
Adi Shmueli	Director of Marketing	1.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: IINN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dagi Ben-Noon	Co-Founder	4.7yrs	US$521.19k	1.77% $ 444.4k
Joe Hayon	Co-Founder	4yrs	US$523.73k	3.4% $ 854.9k
Benad Goldwasser	Independent Chairman of the Board	3.8yrs	Veri yok	0.70% $ 175.9k
Lior Amit	Independent Director	3.3yrs	Veri yok	0.14% $ 36.3k
Limor Rozen	Independent Director	3.3yrs	Veri yok	0.14% $ 36.3k
Tal Parnes	Independent Director	3.3yrs	Veri yok	0.14% $ 36.3k
Orit Jacob	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Avraham Abutbul	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Dekel Stavi	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Sharon Marx	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yael Lichter	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephane Ledot	Member of Scientific Advisory Board	3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IINN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Inspira Technologies Oxy B.H.N Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Less than half of directors are independent

Recent updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Inspira Technologies OXY B.H.N. Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

New major risk - Shareholder dilution

Inspira Technologies OXY B.H.N. Ltd. Receives Israeli Regulatory Approval for the INSPIRA ART100 System

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Announces Start of Production of the Inspira™ Art100

Price target increased by 44% to US$13.00

Inspira™? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections

Inspira™ Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies

Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

New minor risk - Share price stability

Inspira Technologies Oxy B.H.N. Ltd. Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for A New Disposable Perfusion Market Opportunity

Inspira Technologies Oxy B.H.N. Ltd. has completed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies OXY BHN Ltd. Announces 95% Accuracy Results for HYLA™? Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Oxy B.H.N. Ltd. Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology

Inspira Technologies OXY BHN Ltd. Announces the Grant of an Additional Patent by the U.S. Patent and Trademark Office for its Respiratory Medical Device, the INSPIRAART500

Inspira Technologies Unveils the Inspira™ Art Line of Medical Devices At the World's Largest Extracorporeal Life Support Conference

Inspira™? Announces 510(k) FDA Submission of INSPIRA™? ART100 Towards Commercialization

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira Technologies Oxy B.H.N. Ltd. to Reveal the New ALICE Device at the World's Largest Extracorporeal Life Support Conference

Inspira™ Technologies OXY B.H.N. Ltd. Develops the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira(TM) Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA(TM) Blood Sensor

Inspira Technologies Receives Patent by U.S. Patent Office for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use

Inspira Technologies Oxy B.H.N. Ltd. Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Less than half of directors are independent

Inspira Technologies Oxy B.H.N. Ltd. Receives Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Oct 18, 2022

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira Technologies Oxy B.H.N. Ltd. Announces Changes in Management

Inspira Technologies reports 1H results

Inspira™ Technologies Reveals Next Generation Liby™ ECMO

Inspira Technologies Develops A Non-Invasive Blood Sensor

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Chairman of the Board notifies of intention to sell stock

Less than half of directors are independent

Inspira Technologies Appoints Daniella Yeheskely-Hayon as the New Chief Technology Officer

Inspira Technologies Oxy B.H.N. Ltd. Lists a Component of its ART and ECLS Systems on the U.S. Food and Drug Administration Class I 510(K) Exempt List

Inspira Technologies Oxy B.H.N. Ltd. Files A Pct Patent Application for Its Flagship Art Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation

Inspira Technologies Oxy B.H.N. Ltd. has completed an IPO in the amount of $16.029091 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş